A collection unique in Europe
Launched within the framework of Investments for the Future by the National Research Agency (ANR), at the heart of the French Government’s Plan Cancer and supported by the National Cancer Institute (INCa), the CRYOSTEM’s project was initiated in 2011 under the auspices of the Francophone Society of Marrow Transplantations and Cellular Therapy (SFGM-TC) to accelerate research in the area of complications of Hematopoietic Stem Cell Transplantation (HSCT), previously called bone marrow transplantation. Today, CRYOSTEM brings together all French transplant units, 28 Biological Resource Centers (CRB) as well as more than 400 French research and healthcare players in the field of severe blood diseases.More
CRYOSTEM partnering centers
(transplant units and biological resource centers)
Today the CRYOSTEM community offers academic and industrial research teams, a collection of almost 200 000 samples to address life-threatening complications of HSCT.
CRYOSTEM regulatory and operational manager
CRYOSTEM is a wonderful opportunity for researchers to better understand the biological mechanisms, to improve the prevention and the management of the complications of HSCT.
Dr. Claire Galambrun
Department of Pediatric Hematology,
The Timone Hospital
CRYOSTEM could play a significant role to predict the transplant toxicity.
Dr. Boris Calmels
Department of Hematology and Cell Therapy
Founding Member of CRYOSTEM
Throughout the year, CRYOSTEM encourages researchers to apply to gain access to the collection.
Dr. Emilie Robert
CRYOSTEM strategy and development manager
What interests us it is being able to discriminate early before transplantation between patients who are going to benefit from the treatment.
Pr. Régis Peffault de Latour
Department of Hematology,
The Saint Louis Hospital,
Founding Member of CRYOSTEM
An informed patient is a better armed patient : at U2T, we use games to increase patients awareness of the HSCT complications.
Department of Onco-Hematology,
of transplanted patients in France
- 5 575 Recipients
- 2 378 Donors
- 17 464 Sampling
- 50 140 Samples (199 571 aliquots)
- 6 904 Cleared aliquots
News & events
New publication and scientific valorization#GVHD research & scientific valorization. Publication of a promising study…
HTC Day 2019 – CRYOSTEM Scientific day – may, 14th 20194th Edition of the HTC Project Scientific Day #HTCDAY19 Organized…
CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 2015 Mar 12;125(11):1830-9. doi: 10.1182/blood-2014-09-599159.
Current issues in chronic graft-versus-host disease. Blood. 2014 Jul 17;124(3):374-84. doi:10.1182/blood-2014-01-514752.
Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood. 2013 Sep 5;122(10):1802-12. doi: 10.1182/blood-2013-02-482539.
Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood. 2012 Jun 14;119(24):5909-17. doi: 10.1182/blood-2011-12-397968.